

Date: March 31, 2021

To,	То,
The Manager,	The Department of Corporate Service,
Listing Department,	BSE Limited,
National Stock Exchange of India	1 st Floor, New Trading Ring,
Limited,	Rotunda Building,
Exchange Plaza, C-1, Block-G, Bandra-	Phiroze Jeejeebhoy Tower,
Kurla Complex, Bandra (E),	Dalal Street,
Mumbai-400 051.	Mumbai-400 001.
Scrip Code - LINCOLN	Scrip Code - 531633

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed a Media Release titled "Promoters of Lincoln Pharma increases promoter group holding by 4.9% during FY 20-21 to 37.25%."

We request you to kindly take the above on record.

Thanking you,

Yours faithfully,

FOR LINCOLN PHARMACEUTICALS LIMITED

COMPANY SECRETARY

Encl: a/a

Regd. Office: "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India Phone: +91-79-4107 8000 | Fax: +91-79-4107 8062 | CIN L24230GJ1995PLC024288 E-mail: info@lincolnpharma.com | Website: www.lincolnpharma.com









Media Release

Promoters of Lincoln Pharma increases promoter group holding by 4.9% during FY 20-21 to 37.25%.

Acquires 9.8 lakh shares from open market at average price of Rs. 225.6 per share

Highlights:-

- ICRA in its recent report has upgraded rating on long-term bank facilities to ICRA A and short-term facilities to ICRA A1 backed by steady growth in margins and improvement in risk profile
- Company becomes a Zero net-debt company; Plans to expand export network in 90 plus countries

March 31 2021:- Promoter group of Lincoln Pharmaceuticals Ltd, one of India's leading healthcare companies is gradually increasing their holding in the company. During the FY 2020-21, the promoter group has bought 9.8 lakh shares from the Secondary market - at an average price of Rs. 225.6 per share. With this, promoter holding in the company has increased to 37.25% - rise of 4.9% (490 bps) from 32.35% as of 31 March 2020. Rating agency ICRA has recently upgraded the company's long-term and short-term bank facilities to A and A1 respectively.

The Securities and Exchange Board of India under creeping acquisition allows promoters of a listed company to enhance promoter group holding by 4.9% in a financial year. Share price of Lincoln Pharmaceuticals Ltd was Rs. 222.6 per share on 30 March 2021. Share price of the company have risen 160% from March 2020 low of Rs. 85 per share and also made a high of Rs. 283 per share.

"We are committed and plan to gradually up the promoter holding ideally to a majority mark over the next 3-5 years. Our company is growing from strength to strength and delivering robust operational and financial performance while maintaining healthy growth in revenue, margins and profitability and expects to continue the growth momentum in the coming years. Our strategic growth initiatives, product and geographical expansion, EU approval and operational efficiency are likely to maximise value for all stakeholders in the near to medium term. The recent upgrade by ICRA for the company's long-term and short-term ratings further testifies the strong foundation of the group," said Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited.

Rating agency in its report has stated that the upgrade in ratings takes into account the improvement in the group's financial risk profile in FY2020 and 9MFY2021, backed by steady growth in scale and margins. The report further states that, Healthy profitability and limited capex outgo have improved the coverage indicators and liquidity, resulting in healthy built up of free cash/liquid investments.

During FY20, the company has become a zero net-debt company. Company has received EU approval and plans to enter the EU markets very soon with its dermatology, gastro and pain management products. Company currently exports to more than 60 countries and plans to expand to 90 plus countries.

Regd. Office: "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India **Phone:** +91-79-4107 8000 | **Fax:** +91-79-4107 8062 | **CIN** L24230GJ1995PLC024288

E-mail: info@lincolnpharma.com | Website: www.lincolnpharma.com

Factory: 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

Ta.: Kalol, Dist. Gandhinagar, (Guj.) | Phone: +91-79-49135000 | E-mail: khatraj@lincolnpharmace...



IMEDABAD





For the nine months ended December 2020, the company has posted a net profit of Rs. 48.6 crore as against net profit of Rs. 40.3 crore, growth of 20.7%. Net revenue also grew by 10% Y-o-Y to Rs. 339.8 crore in nine months ended December 2020.

About Lincoln Pharmaceuticals Limited: https://www.lincolnpharma.com/

Providing Affordable and Innovative medicines for healthier lives.

Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. The company have its strong presence in Domestic market with good strength of own field force and also exports to more than 60 Countries.

Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with a vision for nurturing innovations and bringing them to Indian patients at an affordable cost to create "Healthcare for All".

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by WHO-GMP and ISO-9001: 2015. Recently company has also received European Union (EU) GMP certification for its manufacturing facility which will allow it to market its products in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

Company's key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filled 25 plus patent applications and is awarded seven patents. R&D centre of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-theart devices and equipment for internal physical, chemical and microbiological analysis of all products.

Going green, company has also set up a new Solar Plant of 1 MW at factory's rooftop in addition to two windmills. This way we are producing renewable energy to our consumption nearly 65% resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization.

For further information please contact:

Gopal Modi / Rupesh Panchal ColdCoco Consultancy, Ahmedabad 9099030184 / 9925023103 gopal@coldcococonsultancy.com rupesh@coldcococonsultancy.com Darshit A. Shah (Chief Financial Officer)
Lincoln Pharmaceuticals Limited, Ahmedabad
+91-79-4107-8048
darshit@lincolnpharma.com

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India **Phone :** +91-79-4107 8000 | **Fax :** +91-79-4107 8062 | **CIN** L24230GJ1995PLC024288

E-mail: info@lincolnpharma.com | Website: www.lincolnpharma.com

Factory: 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

Ta.: Kalol, Dist. Gandhinagar, [Guj.] | Phone: +91-79-49135000 | E-mail: khatraj@lincolnpharma.com



